Sökning: "ki-67"
Visar resultat 1 - 5 av 82 avhandlingar innehållade ordet ki-67.
1. Prognostic factors in soft tissue sarcoma. Tissue microarray for immunostaining, the importance of whole-tumor sections and time-dependence
Sammanfattning : In adult soft tissue sarcoma (STS) of the extremities and trunk wall, improved prognostic factors are needed to identify patients at high-risk for metastasis. Various factors are included in the many prognostic systems currently in use and the prognostic value of immunohistochemical (IHC) expression of biological markers is unclear. LÄS MER
2. Aggressive lymphoma
Sammanfattning : Aggressive lymphoma is a rapidly growing tumour of lymphocyte origin, potentially curable with chemotherapy. In a trial by the Nordic Lymphoma Group, 405 patients with aggressive lymphoma were included, and randomised to receive either the standard chemotherapy regimen, CHOP, or a weekly multidrug regimen, MACOP-B. LÄS MER
3. Cyclin A and cyclin E as prognostic factors in early breast cancer
Sammanfattning : Breast cancer is one of the most common malignancies in women. Due to early detection and the use of screening programs approximately 60% of all new cases lack lymph node involvement. Today, a substantial proportion of these women will be offered adjuvant systemic chemotherapy. LÄS MER
4. Diffuse large B-cell lymphoma – studies on immunohistochemical and clinical prognostic factors
Sammanfattning : DLBCL, the most common lymphoma entity, is a potentially curable but heterogeneous disease. Most studies concerning therapy and prognostic factors have been performed on selected patient materials. It is important to identify immunohistochemical biomarkers which could add prognostic information to clinical factors. LÄS MER
5. Endosonography and pretreatment tumor profiling - from sampling, staining, to sequencing
Sammanfattning : Background and aims: Endosonography-guided fine needle aspiration (EUS-FNA) is imperfect in diagnosing solid pancreatic lesions (SPL) and subepithelial lesions (SEL) including gastrointestinal stromal tumors (GIST). In GISTs, imatinib therapy is effective only in variants of oncogenes KIT and PDGFRA. LÄS MER